查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1363063

抗病毒藥物市場規模、佔有率和趨勢分析報告：按類型、藥物類別、配銷通路、用途、區域、細分趨勢，2023-2030

Antiviral Drugs Market Size, Share & Trends Analysis Report By Type (Branded, Generics), By Drug Class, By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Application, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

抗病毒藥物市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球抗病毒藥物市場規模將達到620.5億美元，2023年至2030年年複合成長率為-1.99%。

這是由病毒性疾病患病上升以及政府不斷增加的與開發新療法以減少感染疾病傳播相關的舉措所推動的。此外，加強研發力度以及擴大免疫和聯合治療等最新細節預計將推動市場成長。病毒大流行的可能性凸顯了對廣譜抗病毒藥物的需求，例如直接作用的抗病毒藥物，可以立即大規模部署，以阻止病毒的傳播，直到有足夠的疫苗接種為止。抗病毒重磅療法的出現徹底改變了各種病毒感染疾病的治療方法。

值得注意的例子包括在丙型肝炎治療中引入直接作用抗病毒藥物（DAA），例如Sovaldi（索磷布韋）、Harvoni（雷迪帕韋/索磷布韋）和Epclosa（索磷布韋/維帕他韋），它透過實現更高的治癒率徹底改變了這一領域與以前相比，治療速度更快、治療時間更短、副作用更少。這些藥物已獲得重磅炸彈地位，因為它們可以有效治癒丙型肝炎並解決未滿足的醫療需求。政府對抗病毒藥物的配合措施包括資助研究和開發、簡化核准和緊急使用授權的法規流程、戰略儲備以備不時之需，以及加快開發有效的抗病毒治療方法，其中包括與行業和學術機構合作以提高可用性。

例如，2022年5月，美國國立衛生研究院下屬的國家過敏和感染疾病研究所（NIAID）針對大流行病病原體建立了9個抗病毒藥物發現（AViDD）中心，並提供了約5.77億美元提高經濟成長水準。此外，政府機構和主要企業之間合作的加強預計將推動新型抗病毒藥物研發活動的成長。例如，2021 年 6 月，默克公司與美國政府簽訂了 molnupiravir 的採購協議，molnupiravir 是一種用於治療 COVID-19 的在臨床實驗抗病毒藥物。根據協議，如果molnupiravir獲得美國FDA緊急使用核准或核准，該公司將獲得12億美元並向美國政府供應約170萬療程的藥物。

此外，市場參與者正在採取策略性配合措施來滿足臨床測試日益成長的需求。大公司正在收購地區性公司以加強其市場地位。正因為如此，這個地區的玩家之間的競爭非常激烈。市場參與者正專注於開發新產品。例如，截至 2023 年 6 月，有超過 900 項研究正在進行抗病毒藥物開發的 2 期、3 期和 4 期臨床試驗。此外，PharmaMar將於2023年4月開始Nereida臨床試驗，使用罹患治療COVID-19的免疫抑制患者，該試驗將在西班牙、義大利、法國、波蘭、匈牙利、希臘和葡萄牙使用，該試驗已獲得核准。

抗病毒藥物市場報告亮點

  • 該品牌類型因其經過驗證的功效、安全性以及核准而廣泛採用，在 2022 年佔據市場主導地位。
  • 按藥物類別分類，由於愛滋病毒/愛滋病等慢性疾病的流行增加了對有效治療藥物的需求，蛋白酶抑制劑細分市場將在 2022 年佔據主導地位。
  • 從配銷通路來看，由於患病人數不斷增加、高齡化以及住院患者數量不斷增加，醫院藥房板塊在2022年將佔據最大的市場佔有率。
  • 由於擁有完善的醫療基礎設施、病毒性疾病的高患病以及治療藥物的快速發展，北美已在市場上確立了區域地位。

目錄

第1章 調查方法和範圍

第2章 執行摘要

第3章 市場變數、趨勢和範圍

  • 市場區隔和範圍
  • 市場體系預測
    • 母市場預測
    • 相關/附隨市場預測
  • 市場趨勢及展望
  • 市場動態
    • 病毒感染疾病的傳播
    • 加強政府應對病毒感染疾病的配合措施
    • 老年人口增加
  • 市場抑制因素分析
    • 昂貴的治療費用
  • 營商環境分析
    • SWOT 分析；要素因素（政治/法律、經濟/技術）
    • 波特五力分析
  • COVID-19感染疾病的影響分析

第4章 按類型分類的業務分析

  • 抗病毒藥物市場：類型變異分析
  • 品牌
  • 通用的

第5章 醫藥類業務分析

  • 抗病毒藥物市場：藥品類別波動分析
  • DNA聚合酶抑制劑
  • 逆轉錄酶抑制劑
  • 蛋白酶抑制劑
  • 神經氨酸酶抑制劑
  • 其他

第6章 配銷通路業務分析

  • 抗病毒藥物市場：配銷通路波動分析
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章 用途業務分析

  • 抗病毒藥物市場：應用變化分析
  • 流感
  • HIV
  • 肝炎
  • 皰疹
  • 其他

第8章 區域業務分析

  • 2022年及2030年抗病毒藥物市場佔有率（按地區）
  • 北美洲
    • SWOT分析
    • 2018-2030年北美抗病毒藥物市場
    • 美國
    • 加拿大
  • 歐洲
    • SWOT分析
    • 歐洲抗病毒藥物市場，2018-2030
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • SWOT分析
    • 2018-2030年亞太地區抗病毒藥物市場
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • SWOT分析
    • 拉丁美洲抗病毒藥物市場，2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • SWOT分析
    • MEA抗病毒藥物市場，2018-2030
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭形勢

  • 公司分類
  • 策略規劃
    • 新產品發布
    • 合夥
    • 獲得
    • 合作
    • 資金籌措
  • 2022年主要企業市場佔有率分析
  • 企業熱力圖分析
  • 公司簡介
    • F. HOFFMANN-LA ROCHE LTD.
    • GSK PLC.
    • ABBVIE, INC.
    • MERCK &CO., INC.
    • JOHNSON &JOHNSON SERVICES, INC.
    • BRISTOL-MYERS SQUIBB COMPANY
    • CIPLA INC.
    • AUROBINDO PHARMA
    • DR. REDDY'S LABORATORIES LTD.
Product Code: GVR-1-68038-389-8

Antiviral Drugs Market Growth & Trends:

The global antiviral drugs market size is expected to reach USD 62.05 billion by 2030, registering a CAGR of -1.99% from 2023 to 2030, according to a new report by Grand View Research, Inc.. This is attributed to the rising prevalence of viral diseases and growing government initiatives pertaining to the development of novel therapeutics to reduce the spread of infections. Furthermore, an increase in R&D efforts and the expansion of more recent & updated details, such as vaccinations and combined therapy, are projected to propel the growth of the market. Potential viral pandemics highlight the need for broad-spectrum antiviral drugs, such as direct-acting antivirals, that can be immediately deployed on a massive scale to halt viral spread until suitable vaccinations are created. Introducing blockbuster therapeutics for antiviral drugs has been transformative in treating various viral infections.

These drugs have demonstrated significant efficacy, widespread use, and substantial revenue generation for pharmaceutical companies.One prominent example is the introduction of Direct-acting Antivirals (DAAs) for the treatment of hepatitis C drugs, such as Sovaldi (sofosbuvir), Harvoni (ledipasvir/sofosbuvir), and Epclusa (sofosbuvir/velpatasvir), revolutionized the field by providing high cure rates, shorter treatment durations, and fewer side effects compared to previous therapies. These drugs achieved blockbuster status due to their effectiveness in curing hepatitis C and addressing a significant unmet medical need. Government initiatives for antiviral drugs include funding for R&D, streamlining regulatory processes for approval and emergency use authorizations, strategic stockpiling for preparedness, and collaborations with industry & academic institutions to accelerate development and ensure accessibility of effective antiviral treatments.

For instance, in May 2022, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, granted around USD 577 million to launch nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern. Moreover, increasing collaborations between government bodies and key players are anticipated to fuel the growth of R&D activities for developing novel antiviral drugs. For instance, in June 2021, Merck & Co., Inc. entered into a procurement agreement with the U.S. government for molnupiravir, an investigational antiviral for COVID-19 treatment. According to the agreement, the company will receive USD 1.2 billion to supply around 1.7 million drug courses to the U.S. government if molnupiravir receives emergency use authorization or approval by the U.S. FDA.

Furthermore, market entities are undertaking strategic initiatives to address the growing demand for clinical tests. Major players are involved in the acquisition of regional players to strengthen their position in the market. Thus, there is significant competition among players in this region. Players in the market are focusing on developing new products. For instance, as of June 2023, over 900 studies are ongoing in phases 2, 3, and 4 of clinical trials for antiviral drug development. Moreover, in April 2023, PharmaMar initiated the Nereida clinical trial using plitidepsin for the treatment of immunosuppressed patients suffering from COVID-19, with trials being approved in Spain, Italy, France, Poland, Hungary, Greece, and Portugal.

Antiviral Drugs Market Report Highlights:

  • The branded type segment dominated the market in 2022 as they are widely adopted due to their proven efficacy, safety profile, and endorsement by healthcare authorities
  • On the basis of drug class, the protease inhibitors segmentdominated the market in 2022 owing to the rising need for effective therapeutics due to the increasing prevalence of chronic diseases, such as HIV/AIDS
  • Based on distribution channel, the hospital pharmacy segment held the largest market share in 2022owing to an increasing number of people suffering from diseases, a rapidly aging population, and a growing number of hospitalizations
  • North America has established a strong regional position in the market due to the presence of well-established healthcare infrastructure,a high prevalence of viral diseases, and rapid advancements in therapeutics

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Information Procurement
  • 1.2. Information or Data Analysis
  • 1.3. Market Scope & Segment Definition
  • 1.4. Market Model
    • 1.4.1. Market Study, By Company Market Share
    • 1.4.2. Regional Analysis

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Increasing prevalence of viral infections
    • 3.4.2. Increasing government initiatives for viral infections
    • 3.4.3. Increasing geriatric population
  • 3.5. Market Restraint Analysis
    • 3.5.1. High cost of treatment
  • 3.6. Business Environment Analysis
    • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis
  • 3.7. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

  • 4.1. Antiviral Drugs Market: Type Movement Analysis
  • 4.2. Branded
    • 4.2.1. Branded Market, 2018 - 2030 (USD Million)
  • 4.3. Generics
    • 4.3.1. Generics Market, 2018 - 2030 (USD Million)

Chapter 5. Drug Class Business Analysis

  • 5.1. Antiviral Drugs Market: Drug Class Movement Analysis
  • 5.2. DNA Polymerase Inhibitors
    • 5.2.1. DNA Polymerase Inhibitors Market, 2018 - 2030 (USD Million)
  • 5.3. Reverse Transcriptase Inhibitors
    • 5.3.1. Reverse Transcriptase Inhibitors Market, 2018 - 2030 (USD Million)
  • 5.4. Protease Inhibitors
    • 5.4.1. Protease Inhibitors Market, 2018 - 2030 (USD Million)
  • 5.5. Neuraminidase Inhibitors
    • 5.5.1. Neuraminidase Inhibitors Market, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Distribution Channel Business Analysis

  • 6.1. Antiviral Drugs Market: Distribution Channel Movement Analysis
  • 6.2. Hospital Pharmacy
    • 6.2.1. Hospital Pharmacy Market, 2018 - 2030 (USD Million)
  • 6.3. Retail Pharmacy
    • 6.3.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
  • 6.4. Online Pharmacy
    • 6.4.1. Online Pharmacy Market, 2018 - 2030 (USD Million)

Chapter 7. Application Business Analysis

  • 7.1. Antiviral Drugs Market: Application Movement Analysis
  • 7.2. Influenza
    • 7.2.1. Influenza Market, 2018 - 2030 (USD Million)
  • 7.3. HIV
    • 7.3.1. HIV Market, 2018 - 2030 (USD Million)
  • 7.4. Hepatitis
    • 7.4.1. Hepatitis Market, 2018 - 2030 (USD Million)
  • 7.5. Herpes
    • 7.5.1. Herpes Market, 2018 - 2030 (USD Million)
  • 7.6. Others
    • 7.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Antiviral Drugs Market Share By Region, 2022 & 2030
  • 8.2. North America
    • 8.2.1. SWOT Analysis
    • 8.2.2. North America Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.2.3. U.S.
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Target Disease Prevalence
      • 8.2.3.3. Competitive Scenario
      • 8.2.3.4. Regulatory Framework
      • 8.2.3.5. Reimbursement Scenario
      • 8.2.3.6. U.S. Antiviral drugs Market, 2018 - 2030 (USD MILLION)
    • 8.2.4. Canada
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Target Disease Prevalence
      • 8.2.4.3. Competitive Scenario
      • 8.2.4.4. Regulatory Framework
      • 8.2.4.5. Reimbursement Scenario
      • 8.2.4.6. Canada Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. SWOT Analysis
    • 8.3.2. Europe Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Target Disease Prevalence
      • 8.3.3.3. Competitive Scenario
      • 8.3.3.4. Regulatory Framework
      • 8.3.3.5. Reimbursement Scenario
      • 8.3.3.6. Germany Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.3.4. UK
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Target Disease Prevalence
      • 8.3.4.3. Competitive Scenario
      • 8.3.4.4. Regulatory Framework
      • 8.3.4.5. Reimbursement Scenario
      • 8.3.4.6. UK Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.3.5. France
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Target Disease Prevalence
      • 8.3.5.3. Competitive Scenario
      • 8.3.5.4. Regulatory Framework
      • 8.3.5.5. Reimbursement Scenario
      • 8.3.5.6. France Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.3.6. Italy
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Target Disease Prevalence
      • 8.3.6.3. Competitive Scenario
      • 8.3.6.4. Regulatory Framework
      • 8.3.6.5. Reimbursement Scenario
      • 8.3.6.6. Italy Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.3.7. Spain
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Target Disease Prevalence
      • 8.3.7.3. Competitive Scenario
      • 8.3.7.4. Regulatory Framework
      • 8.3.7.5. Reimbursement Scenario
      • 8.3.7.6. Spain Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.3.8. Denmark
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Target Disease Prevalence
      • 8.3.8.3. Competitive Scenario
      • 8.3.8.4. Regulatory Framework
      • 8.3.8.5. Reimbursement Scenario
      • 8.3.8.6. Denmark Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.3.9. Sweden
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Target Disease Prevalence
      • 8.3.9.3. Competitive Scenario
      • 8.3.9.4. Regulatory Framework
      • 8.3.9.5. Reimbursement Scenario
      • 8.3.9.6. Sweden Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.3.10. Norway
      • 8.3.10.1. Key Country Dynamics
      • 8.3.10.2. Target Disease Prevalence
      • 8.3.10.3. Competitive Scenario
      • 8.3.10.4. Regulatory Framework
      • 8.3.10.5. Reimbursement Scenario
      • 8.3.10.6. Norway Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. SWOT Analysis
    • 8.4.2. Asia Pacific Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.4.3. Japan
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Competitive Scenario
      • 8.4.3.4. Regulatory Framework
      • 8.4.3.5. Reimbursement Scenario
      • 8.4.3.6. Japan Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.4.4. China
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Competitive Scenario
      • 8.4.4.4. Regulatory Framework
      • 8.4.4.5. Reimbursement Scenario
      • 8.4.4.6. China Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.4.5. India
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Target Disease Prevalence
      • 8.4.5.3. Competitive Scenario
      • 8.4.5.4. Regulatory Framework
      • 8.4.5.5. Reimbursement Scenario
      • 8.4.5.6. India Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.4.6. South Korea
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Target Disease Prevalence
      • 8.4.6.3. Competitive Scenario
      • 8.4.6.4. Regulatory Framework
      • 8.4.6.5. Reimbursement Scenario
      • 8.4.6.6. South Korea Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.4.7. Australia
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Target Disease Prevalence
      • 8.4.7.3. Competitive Scenario
      • 8.4.7.4. Regulatory Framework
      • 8.4.7.5. Reimbursement Scenario
      • 8.4.7.6. Australia Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.4.8. Thailand
      • 8.4.8.1. Key Country Dynamics
      • 8.4.8.2. Target Disease Prevalence
      • 8.4.8.3. Competitive Scenario
      • 8.4.8.4. Regulatory Framework
      • 8.4.8.5. Reimbursement Scenario
      • 8.4.8.6. Thailand Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. SWOT Analysis
    • 8.5.2. Latin America Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.5.3. Brazil
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Competitive Scenario
      • 8.5.3.4. Regulatory Framework
      • 8.5.3.5. Reimbursement Scenario
      • 8.5.3.6. Brazil Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.5.4. Mexico
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Competitive Scenario
      • 8.5.4.4. Regulatory Framework
      • 8.5.4.5. Reimbursement Scenario
      • 8.5.4.6. Mexico Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.5.5. Argentina
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Competitive Scenario
      • 8.5.5.4. Regulatory Framework
      • 8.5.5.5. Reimbursement Scenario
      • 8.5.5.6. Argentina Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • 8.6. MEA
    • 8.6.1. SWOT Analysis
    • 8.6.2. MEA Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.6.3. South Africa
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Competitive Scenario
      • 8.6.3.4. Regulatory Framework
      • 8.6.3.5. Reimbursement Scenario
      • 8.6.3.6. South Africa Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.6.4. Saudi Arabia
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Competitive Scenario
      • 8.6.4.4. Regulatory Framework
      • 8.6.4.5. Reimbursement Scenario
      • 8.6.4.6. Saudi Arabia Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.6.5. UAE
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Competitive Scenario
      • 8.6.5.4. Regulatory Framework
      • 8.6.5.5. Reimbursement Scenario
      • 8.6.5.6. UAE Antiviral Drugs Market, 2018 - 2030 (USD Million)
    • 8.6.6. Kuwait
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Competitive Scenario
      • 8.6.6.4. Regulatory Framework
      • 8.6.6.5. Reimbursement Scenario
      • 8.6.6.6. Kuwait Antiviral Drugs Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
    • 9.2.1. New Product Launch
    • 9.2.2. Partnership
    • 9.2.3. Acquisition
    • 9.2.4. Collabboration
    • 9.2.5. Funding
  • 9.3. Key Company Market Share Analysis, 2022
  • 9.4. Company Heat Map Analysis
  • 9.5. Company Profiles
    • 9.5.1. F. HOFFMANN-LA ROCHE LTD.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. GSK PLC.
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. ABBVIE, INC.
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. MERCK & CO., INC.
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. JOHNSON & JOHNSON SERVICES, INC.
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. BRISTOL-MYERS SQUIBB COMPANY
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. CIPLA INC.
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. AUROBINDO PHARMA
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. DR. REDDY'S LABORATORIES LTD.
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 Global Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 3 Global Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 4 Global Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 5 Global Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 6 Global Antiviral Drugs Market, by Region, 2018 - 2030 (USD Million)
  • Table 7 North America Antiviral Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 9 North America Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 10 North America Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 North America Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 12 U.S. Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 13 U.S. Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 14 U.S. Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 15 U.S. Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 16 Canada Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 17 Canada Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 18 Canada Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Canada Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 20 Europe Antiviral Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 21 Europe Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 22 Europe Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 23 Europe Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 Europe Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 25 Germany Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 26 Germany Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 27 Germany Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 Germany Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 29 UK Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 30 UK Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 31 UK Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 UK Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 33 France Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 34 France Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 35 France Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 France Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 37 Italy Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 38 Italy Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 39 Italy Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 Italy Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 41 Spain Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 42 Spain Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 43 Spain Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Spain Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 45 Denmark Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 46 Denmark Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 47 Denmark Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 48 Denmark Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 49 Sweden Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 50 Sweden Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 51 Sweden Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Sweden Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 53 Norway Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 54 Norway Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 55 Norway Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 Norway Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Antiviral Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 62 China Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 63 China Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 64 China Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 65 China Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 66 Japan Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 67 Japan Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 68 Japan Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 69 Japan Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 70 India Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 71 India Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 72 India Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 India Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 74 South Korea Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 75 South Korea Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 76 South Korea Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 77 South Korea Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 78 Australia Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 79 Australia Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 80 Australia Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 81 Australia Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 82 Thailand Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 83 Thailand Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 84 Thailand Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 85 Thailand Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 86 Latin America Antiviral Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 87 Latin America Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 88 Latin America Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 89 Latin America Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 90 Latin America Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 91 Brazil Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 92 Brazil Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 93 Brazil Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 94 Brazil Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 95 Mexico Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 96 Mexico Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 97 Mexico Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 98 Mexico Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 99 Argentina Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 100 Argentina Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 101 Argentina Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 102 Argentina Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 103 Middle East & Africa Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 107 South Africa Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 108 South Africa Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 109 South Africa Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 110 South Africa Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 111 Saudi Arabia Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 115 UAE Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 116 UAE Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 117 UAE Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 118 UAE Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 119 Kuwait Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 120 Kuwait Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 121 Kuwait Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 122 Kuwait Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain - Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Antiviral Drugs Market Segmentation
  • Fig. 8 Market Snapshot, 2022
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 14 Porter's Five Forces Analysis
  • Fig. 15 Market Penetration Vs Growth Prospect Mapping, 2022
  • Fig. 16 Global Antiviral Drugs Market: Type Movement Analysis
  • Fig. 17 Global Antiviral Drugs Market, by Branded, 2018 - 2030 (USD Million)
  • Fig. 18 Global Antiviral Drugs Market, by Generics, 2018 - 2030 (USD Million)
  • Fig. 19 Global Antiviral Drugs Market: Drug Class Movement Analysis
  • Fig. 20 Global Antiviral Drugs Market, by DNA Polymerase Inhibitors, 2018 - 2030 (USD Million)
  • Fig. 21 Global Antiviral Drugs Market, by Reverse Transcriptase Inhibitors, 2018 - 2030 (USD Million)
  • Fig. 22 Global Antiviral Drugs Market, by Protease Inhibitors, 2018 - 2030 (USD Million)
  • Fig. 23 Global Antiviral Drugs Market, by Neuraminidase Inhibitors, 2018 - 2030 (USD Million)
  • Fig. 24 Global Antiviral Drugs Market, by Others, 2018 - 2030 (USD Million)
  • Fig. 25 Global Antiviral Drugs Market: Distribution Channel Movement Analysis
  • Fig. 26 Global Antiviral Drugs Market, by Hospital Pharmacy 2018 - 2030 (USD Million)
  • Fig. 27 Global Antiviral Drugs Market, by Retail Pharmacy, 2018 - 2030 (USD Million)
  • Fig. 28 Global Antiviral Drugs Market, by Online Pharmacy, 2018 - 2030 (USD Million)
  • Fig. 29 Regional Marketplace: Key Takeaways
  • Fig. 30 Regional Outlook, 2022 & 2030
  • Fig. 31 Global Antiviral Drugs Market: Region Movement Analysis
  • Fig. 32 North America Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 34 Canada Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 35 Europe Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 36 Germany Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 37 UK Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 38 France Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 39 Italy Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 40 Spain Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 41 Denmark Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 42 Sweden Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 43 Norway Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 44 Asia Pacific Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 45 Japan Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 46 China Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 47 India Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 48 Australia Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 49 South Korea Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 50 Thailand Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 51 Latin America Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 52 Brazil Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 53 Mexico Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 54 Argentina Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 55 Middle East and Africa Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 56 South Africa Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 57 Saudi Arabia Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 58 UAE Antiviral Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 59 Kuwait Antiviral Drugs Market, 2018 - 2030 (USD Million)